Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.
Biliary Cancer
DRUG: SPI-1620|DRUG: Docetaxel
Progression free survival, 18 months
Overall response rate, 18 months|Overall survival, 18 months|Duration of Response, 12 months|Safety of SPI-1620 when administered in combination with docetaxel, Periodic physical examinations with vital sign monitoring, safety laboratories and monitoring of adverse events will be performed, 12 months
The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.